Swedbank AB Sells 9,400 Shares of Icon Plc $ICLR

Swedbank AB decreased its position in shares of Icon Plc (NASDAQ:ICLR) by 19.5% in the 4th quarter, HoldingsChannel reports. The firm owned 38,700 shares of the medical research company’s stock after selling 9,400 shares during the quarter. Swedbank AB’s holdings in Icon were worth $7,052,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Sanctuary Advisors LLC lifted its position in Icon by 1.1% during the fourth quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after purchasing an additional 56 shares during the period. Geneos Wealth Management Inc. lifted its position in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares during the period. Spire Wealth Management lifted its position in Icon by 10.1% during the third quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock worth $119,000 after purchasing an additional 62 shares during the period. New Wave Wealth Advisors LLC lifted its position in Icon by 5.1% during the fourth quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after purchasing an additional 72 shares during the period. Finally, Signaturefd LLC lifted its position in Icon by 12.6% during the fourth quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after purchasing an additional 72 shares during the period. Institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

ICLR has been the subject of a number of research reports. Jefferies Financial Group set a $135.00 target price on shares of Icon and gave the stock a “buy” rating in a report on Monday, February 23rd. Bank of America reissued an “underperform” rating and issued a $75.00 target price on shares of Icon in a report on Thursday, February 12th. BMO Capital Markets raised shares of Icon from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $100.00 to $130.00 in a report on Thursday, March 26th. Rothschild & Co Redburn set a $100.00 target price on shares of Icon and gave the stock a “neutral” rating in a report on Tuesday, February 17th. Finally, Robert W. Baird set a $119.00 target price on shares of Icon in a report on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $149.38.

Icon Stock Performance

Icon stock opened at $124.49 on Friday. The business has a 50 day moving average of $108.25 and a 200-day moving average of $147.36. Icon Plc has a 1 year low of $66.57 and a 1 year high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The company has a market capitalization of $10.05 billion, a P/E ratio of 16.85, a P/E/G ratio of 3.25 and a beta of 1.23.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.